REGULATORY

Zyprexa under PMDA Review for Risk of Drug-Induced Hypersensitivity Syndrome

July 19, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Pharmaceuticals and Medical Devices Agency (PMDA) said on July 15 that it is reviewing the risk of drug-induced hypersensitivity syndrome for the anti-psychotic Zyprexa (olanzapine) - a move that is likely to result in label changes. Drug-induced hypersensitivity syndrome…

To read the full story

4 Bcr-Abl TKIs Ordered to Add Risk of HBV Reactivation in Labels: MHLW
August 5, 2016

REGULATORY

LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…